Search clinical trials for: Pemigatinib 4.5 MG

Total 12006 results

HonorHealth Research Institute
Incyte Corporation

Withdrawn

Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas

Pancreas Cancer

United States
Biozeus Biopharmaceutical S.A.

Not yet recruiting

Evaluation of the Efficacy, Safety and Tolerability of BZ371A in Women With Sexual Arousal Disorder

Female Sexual Dysfunction | Female Sexual Arousal Disorder
GlaxoSmithKline

Completed

A New Oral Treatment For Type II Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, Germany, Canada, Sweden, Latvia, Finland, Greece, Romania, Czechia, Puerto Rico
USDA Beltsville Human Nutrition Research Center
Penn State University

Completed

The Dose-Response Effects of Lean Beef in a Mediterranean-Style Dietary Pattern on Cardiovascular Disease Risk Factors

Healthy Volunteers

United States
Hoffmann-La Roche

Completed

A Study of RO4917523 in Patients With Fragile X Syndrome

Fragile X Syndrome

France, Spain, United States, Peru, Canada, United Kingdom, Chile, Argentina, Mexico, Sweden
PharmaMar
Apices Soluciones S.L.

Completed

Extension Study in a Cohort of Adult Patients With COVID-19 Infection (E-APLICOV-PC)

COVID-19 Infection

Spain
Acerus Pharmaceuticals Corporation

Completed

Efficacy of an Intranasal Testosterone Product

Hypogonadism

United States
The First Affiliated Hospital of Soochow University

Recruiting

A Single-Arm Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients

Non-Small Cell Lung Cancer

China
Sun Yat-sen University

Not yet recruiting

A Single Arm, Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standard Therapy Failure the FGFR Variant

Locally Advanced Unresectable Gastric Cancer

China
Wuhan Union Hospital, China

Recruiting

A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy

Gastric and Colorectal Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement

Cholangiocarcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations

Solid Tumor

China
Janssen Research & Development, LLC

Completed

A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease

Respiratory Syncytial Viruses

Taiwan, Belgium, United Kingdom, Argentina, Panama
The First Affiliated Hospital of Guangzhou Medical...
Sinotau Pharmaceutical Group

Completed

Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors

Malignant Solid Tumors

China
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers

Healthy

United States
Hoffmann-La Roche

Completed

MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy

Major Depressive Disorder

Germany, United States, Taiwan, Mexico, Poland, Russian Federation, Chile, Japan, Romania
Zhejiang Hisun Pharmaceutical Co. Ltd.

Unknown

HPPH Photodynamic Therapy for Patients With Esophageal Cancer (HPPH)

Esophageal Cancer

China
Institut für Klinische Krebsforschung IKF GmbH...
Incyte Biosciences International Sàrl

Recruiting

Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements

Intrahepatic Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Gene Translocation | FGFR2 Gene Rearrangement

Germany
The Fourth Affiliated Hospital of Zhejiang University...
Second Affiliated Hospital, School of Medicine, Zhejiang University

Recruiting

Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer

China
Incyte Corporation

Terminated

Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)

Advanced or Metastatic Solid Tumors | FGFR Mutations | FGFR Translocations

United States
Incyte Corporation
H. Lee Moffitt Cancer Center and Research Institute

No longer available

Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer
The First Affiliated Hospital of Xiamen University

Recruiting

A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy

Advanced Non-Small Cell Lung Cancer

China
Tianjin Medical University Second Hospital

Recruiting

Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors

Solid Tumor | FGF Receptor Gene Mutation | FGF Amplification | FGF Receptor Gene Family Rearrangement | FGF Receptor Gene Translocation

China
Tianjin Medical University Cancer Institute and...

Recruiting

Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations

Gastrointestinal Cancer

China
European Association of Urology Research Foundation
Incyte Biosciences International Sàrl; AMS Advanced Medical Services GmbH; High...

Terminated

Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery (PEGASUS)

Urothelial Cancer

Italy
Zhejiang Cancer Hospital

Recruiting

A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer (Excluding Biliary Tract Cancer) Patients With FGFR Alterations Who Have Failed Standard Therapy

Gastrointestinal Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations

Breast Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Phase I Study of Direct Coagulation Factor Xa Inhibitor SYHA136 Tablets in Chinese Healthy Volunteers

Venous Thrombosis
Bausch Health Americas, Inc.

Completed

(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Carina Biotech Limited

Recruiting

A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer

Colorectal Cancer Metastatic

Australia
Santen Inc.

Completed

A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration (PAVE)

Age-Related Macular Degeneration

United States
Andrew J. Armstrong, MD

Completed

The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer (CATCH)

Prostate Cancer

United States
Pfizer

Completed

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Korea, Republic of, Canada, United States, Australia, United Kingdom, Belgium
Sidney Kimmel Comprehensive Cancer Center at Johns...
Incyte Corporation

Recruiting

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Bladder Cancer | NMIBC | Urothelial Carcinoma Recurrent | Non-Muscle Invasive Bladder Cancer

United States
Trevena Inc.

Completed

Pharmacokinetics and Pharmacodynamics of TRV130, Morphine, and Placebo in Healthy Subjects

Pain, Acute

United States
Northwestern University

Completed

A Trial Comparing Combined Spinal- Epidural Dosing Strategies for External Cephalic Version

Pain | Pregnancy

United States
Novo Nordisk A/S

Completed

A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects

Diabetes Mellitus, Type 2 | Diabetes

China
RemeGen Co., Ltd.

Completed

A Study of RC48-ADC in Subjects With Advanced Breast Cancer

Advanced Breast Cancer

China
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity

Obesity | Overweight
Rothman Institute Orthopaedics

Completed

A Comparison of Steel and Bioabsorbable Screw Fixation of Lisfranc Foot Injuries (Lisfranc)

Joint Instability

United States
Incyte Corporation

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

MPN (Myeloproliferative Neoplasms)

United States, France, United Kingdom, Spain, Canada, Japan, Germany, Switzerland, Belgium, Austria, Italy
Incyte Corporation

Completed

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

UC (Urothelial Cancer)

United States, Netherlands, Spain, Denmark, Belgium, Israel, Italy, Germany, France, Japan, United Kingdom
Incyte Corporation

Terminated

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Solid Tumor Malignancy

United States, France, United Kingdom, Italy, Korea, Republic of, Japan, Spain, Israel, Denmark, Germany, Switzerland
Incyte Corporation

Completed

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

Cholangiocarcinoma

United States, France, Italy, United Kingdom, Germany, Taiwan, Spain, Belgium, Israel, Korea, Republic of, Japan, Thailand
Incyte Corporation

Completed

A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)

Solid Tumors

Japan
Lund University Hospital

Not yet recruiting

A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) (PERELI)

Dedifferentiated Liposarcoma

Sweden, Norway
Incyte Corporation
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Recruiting

Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. (POD1UM-204)

Endometrial Cancer

United States, Belgium, France, Georgia, Greece, Italy, Germany, China
Incyte Corporation

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)

Glioblastoma | Adult-type Diffuse Gliomas

United States, Spain, Italy, United Kingdom, Germany, Japan, France, Netherlands, Denmark
AstraZeneca

Terminated

GALLANT 7 Tesaglitazar Add-on to Sulphonylurea

Type 2 Diabetes

France, Korea, Republic of, South Africa, Spain, United Kingdom, Vietnam, Norway, Israel, Philippines, Australia
Incyte Corporation

Completed

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration (FIGHT-210)

Non-Small Cell Lung Cancer (NSCLC)

Spain, United States, Italy, Germany, France

3

Subscribe